In a Milestone for A.L.S., a Treatment Helps Some Patients Improve

May 6, 2026

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by the FDA for this rare genetic form of ALS, delays symptom progression and death and leads to stabilization or improvement in some, according to a study by WashU Medicine researchers and their collaborators.